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Abstract
Background: Intrathecal (IT) morphine provides excellent post-operative analgesia, but causes
multiple side effects including nausea and vomiting (PONV), pruritus and respiratory depression,
particularly at higher doses. The lowest effective dose of spinal morphine in patients undergoing
total knee arthroplasty is not known.
Methods: We evaluated the analgesic efficacy and side effect profile of 100 – 300 μg IT morphine
in patients undergoing elective total knee replacement in this prospective, randomized, controlled,
double-blind study. Sixty patients over the age of 60 undergoing elective knee arthroplasty were
enrolled. Patients were randomized to receive spinal anaesthesia with 15 mg Bupivacaine and IT
morphine in three groups: (i) 100 μg; (ii) 200 μg; and (iii) 300 μg.
Results: Both 200 μg and 300 μg IT morphine provided comparable levels of postoperative
analgesia. However, patients that received 100 μg had greater pain postoperatively, with higher pain
scores and a greater requirement for supplemental morphine. There were no differences between
groups with regard to PONV, pruritus, sedation, respiratory depression or urinary retention.
Conclusion: Both 200 μg and 300 μg provided comparable postoperative analgesia, which was
superior to that provided by 100 μg IT morphine in patients undergoing total knee arthroplasty.
Based on these findings, we recommend that 200 μg IT morphine be used in these patients.
Trial registration: ClinicalTrials.gov Identifier NCT00695045
Background
The provision of high quality postoperative analgesia after
total knee arthroplasty continues to present a challenge.
Systemic opioids can cause post operative nausea and
vomiting, sedation, and respiratory depression, which
may be especially undesirable in older patients with co-
existing respiratory disease, such as patients undergoing
major joint replacement surgery. Intrathecal (IT) opiates
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are a useful option in patients undergoing knee arthro-
plasty, and can markedly reduce postoperative opioid
requirements [1-3].
However, the use of IT morphine may be associated with
a number of distressing side effects e.g. pruritus, urinary
retention, nausea and vomiting [3-7], and potentially life-
threatening adverse effects i.e. delayed respiratory depres-
sion [2,3,8,9]. Postoperative nausea and vomiting
(PONV) following IT morphine may prove particularly
difficult to control [10], perhaps as a result of the poten-
tial for IT morphine to delay gastric emptying [5]. The
hydrophilic properties of morphine contribute to both
the longevity of its analgesic action and also the risk of late
respiratory depression due to rostral spread when admin-
istered intrathecally. Profound late respiratory depression
has been reported in a number of earlier studies, albeit
following larger doses of spinal morphine than is used in
current practice [11].
The efficacy of doses of IT Morphine of 300 μg or greater,
in patients undergoing total knee arthroplasty, has been
well demonstrated [2,3]. However, the incidence of
PONV is high, with an incidence of 60% reported [10]. Of
greater concern is the potential for respiratory depression,
even with doses as low as 300 μg of IT Morphine [2,12].
The potential for lower doses of IT Morphine to provide
effective analgesia, while reducing postoperative side-
effects, remains unclear. One recent study demonstrated
that 500 μg intrathecal morphine produced better analge-
sia than 200 μg after knee replacement [1]. Rathmell et al
could not find evidence that doses of IT morphine up to
300 μg provided significant analgesia in this population
[13]. Conversely, Cole et al demonstrated that 300 μg IT
morphine did produce effective analgesia following total
knee arthroplasty [2].
The aim of this study was to determine the analgesic effi-
cacy and side-effects profile of 100 μg and 200 μg of IT
morphine, in comparison to 300 μg, in patients undergo-
ing elective total knee arthroplasty.
Methods
After obtaining approval by the Hospital Ethics Commit-
tee, and written informed patient consent, we enrolled
ASA physical status I-III patients scheduled for elective
total knee arthroplasty in a prospective, randomized, dou-
ble blind, controlled clinical trial. Exclusion criteria
included non-suitability for spinal anaesthesia as deemed
by the anaesthetist providing care for the patient; history
of allergy or severe nausea with opioid analgesics or local
anesthetic agents; or any medical condition resulting in
ASA status greater than III. All patients received spinal
anesthesia. The allocation sequence was generated by ran-
dom number tables, and the allocation concealed in
sealed envelopes, which were not opened until patient
consent had been obtained. Patients were randomized to
receive one of three IT doses of preservative free mor-
phine: 100 μg, 200 μg, and 300 μg.
No patient received premedication. Spinal anesthesia was
performed with the patient in the sitting position at the
L3/4 intervertebral space utilizing a 25 gauge Whitacre
needle. Patients were administered 15 mg of hyperbaric
bupivacaine (Marcain Heavy®, AstraZeneca Group, Luton,
UK), and either 100 μg, 200 μg or 300 μg of preservative
free morphine into the intrathecal space, depending on
group allocation. A total volume of 4 ml was administered
to each patient, with the balance of the IT injectate com-
posed of 0.9% NaCl. The dose of IT morphine adminis-
tered was not noted in the patients anesthesia record;
however this was documented in a sealed envelope
attached to the patients anesthesia record which could be
opened in case of an adverse event. All patients received
40% oxygen via face mask for the duration of the proce-
dure. Standard monitoring, including non-invasive blood
pressure, electrocardiogram, and oxygen saturations were
used in all patients for the duration of surgery.
At the end of the procedure, all patients received 100 mg
of diclofenac sodium per rectum, and were then trans-
ferred to a High Dependency Unit (HDU) for a period of
24 hours post-operatively. All patients received nurse
administered 2 mg intravenous morphine bolus on
demand. Each administration was initiated by patient
request and a minimal interval of ten minutes was
required between of each morphine bolus. First line treat-
ment of PONV consisted of prochlorperazine 12.5 mg by
intramuscular injection. If this proved ineffective second
line therapy consisted of 4 mg of ondansetron by intrave-
nous injection. Each administration was initiated by
patient request and a minimal interval of one hour was
required between administration of first and second line
agents. Treatment for pruritus consisted of promethazine
20 mg by intramuscular injection six hourly and treat-
ment in all cases was initiated upon patient request.
Naloxone was reserved for treatment of pruritus that was
resistant to promethazine therapy.
Patients were monitored for 24 hours by the HDU nursing
staff, who were unaware of the patient allocation. Assess-
ment parameters included severity of postoperative pain,
and the presence and severity of postoperative nausea and
vomiting (PONV), pruritus, sedation, and respiratory
depression. The primary outcome variable, the severity of
pain in the first 24 h postoperatively, was assessed every 4
hours utilizing a Visual Analogue Scale (VAS) and by the
amount of supplemental morphine required in the first
24 hours. In addition, the time to first request for supple-
mental analgesics was recorded.BMC Anesthesiology 2008, 8:5 http://www.biomedcentral.com/1471-2253/8/5
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The presence and severity of PONV was assessed every 4
hours using an ordinal scale [0 = no nausea; 1 = mild; 2 =
moderate; 3 = severe; 4 = Vomiting]. In addition, the time
to first request for antiemetic therapy, and total amount of
supplemental antiemetic administered, was recorded. The
presence and severity of pruritus was assessed every 4
hours using an ordinal scale [0 = no itch; 1 = mild; 2 =
moderate; 3 = severe]. The time to first request for therapy
for pruritus, and total amount of promethazine adminis-
tered, were recorded.
Respiratory rate and arterial oxygen saturation were
assessed on a continuous basis over the 24 hour post-
operative period. The incidence of (i) reduced respiratory
rate, defined as respiratory rate < 12 breaths per minute;
and (ii) mild (SaO2 < 94% on room air) moderate (SaO2
< 90% on room air) and severe (SaO2 < 85% on room air)
arterial hypoxemia were recorded. At each 4 hourly data
collection point, the lowest respiratory rate and lowest
arterial oxygen saturation in the previous 4 hours were
recorded.
Sedation was scored according to the following scale (1 =
alert; 2 = calm; 3 = drowsy; 4 = sleeping, easily arousable;
5 = sleeping, difficult to arouse) and the need for urethral
catheterization (defined as absence of spontaneous void-
ing 8 h after surgery and urine volume at catheterization
of >400 ml) was recorded.
Statistical analysis
We based our sample size estimation on the postoperative
morphine requirement. We considered that a clinically
important reduction would be a one third decrease in
postoperative morphine requirements. Based on pilot
studies we projected this reduction to be 5 mg, with a pro-
jected standard deviation of 5 mg. Based on these figures,
using an α = 0.05 and β= 0.2, for an experimental design
incorporating three equal sized groups, we estimated that
20 patients would be required per group. We therefore
aimed to enroll 60 patients into this study.
All analyses were performed on an intention-to-treat
basis. The analysis was preformed using Sigmastat 3.5
(Systat Software, San Jose, CA, USA). Demographic data
were analyzed using one way analysis of variance
(ANOVA), ANOVA on ranks, or χ2 analysis where applica-
ble. For VAS data, group comparisons were performed at
each time point using one way ANOVA with post hoc
comparisons using Student-Newman-Keuls. Area under
the VAS-time curve (AUC) was calculated by the trapezoi-
dal method for each patient and compared using one way
ANOVA. Ordinal data were analyzed using ANOVA on
ranks with post hoc comparisons performed using Mann
Whitney U test with the Bonferroni correction for multi-
ple comparisons. The incidence of side-effects such as pru-
ritus was compared using the Chi squared test for multiple
variables.
Continuous data are presented as means ± standard error
of the mean (SEM), ordinal data are presented as medians
± quartiles (interquartile range), and categorical data are
presented as raw data or as frequencies. The α level for all
analyses was set as P < 0.05.
Results
Eighty patients were assessed for eligibility to participate
in the study [See Additional file 1]. Of these 80 patients,
61 fulfilled eligibility criteria and were asked to partici-
pate. One patient refused consent, and the remaining 60
were included in the study. The 60 patients recruited to
participate in the study were equally distributed between
the groups and there were no between group demo-
graphic differences (Table 1). All patients randomized to
treatment allocation completed the study, and their data
was included in the analysis. Of the 19 patients that were
not eligible for inclusion, 15 had been deemed by their
anaesthetist not to be suitable for spinal anaesthesia,
while 4 patients had a history of opioid induced nausea
and vomiting.
Both 200 μg and 300 μg of IT morphine provided compa-
rable analgesia, in terms of postoperative VAS scores (Fig-
ure 1), median amount of supplemental morphine
Table 1: Demographic data and perioperative factors.
Variable 100 μg IT Morphine 200 μg IT Morphine 300 μg IT Morphine
Number of Patients 20 20 20
Age (yr) 69.2 ± 1.6 70.6 ± 2.0 73.9 ± 1.3
Weight (kg) 84.0 ± 2.3 75.7 ± 2.8 86.2 ± 3.4
Gender (m/f) 8/12 8/12 11/9
Duration of Procedure (mins) 101.3 ± 9.0 94.5 ± 7.4 95.8 ± 7.6
24 hr Blood Loss (mL) 518.0 ± 22.7 498.0 ± 27.6 526.5 ± 29.5
Fluids Administered in 24 hrs (Litres) 5.2 ± 0.2 5.3 ± 0.2 5.6 ± 0.2
Data represented as Mean +/- SEM.
Abbreviations: IT, intrathecal.BMC Anesthesiology 2008, 8:5 http://www.biomedcentral.com/1471-2253/8/5
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required (Figure 2), and time to first request for supple-
mental analgesia (Table 2). In contrast, patients that
received 100 μg had lower quality analgesia compared to
the patients that received 200 μg or 300 μg of IT Mor-
phine. The area under the VAS-time curve was signifi-
cantly greater for the patients that received 100 μg (41.1 ±
6.7) compared to the patients that received 200 μg (22.2
± 3.8) or 300 μg (18.6 ± 4.2) of IT Morphine (P = 0.006,
One way ANOVA) (Figure 1). Postoperative pain scores
were higher in the group that received 100 μg compared
to the patients that received 200 μg or 300 μg of IT Mor-
phine (Figure 1). Median supplemental morphine
requirements were significantly lower in the groups that
received 200 μg and 300 μg compared to that which
received 100 μg of IT morphine (Figure 2).
There was no evidence of significant respiratory depres-
sion at any of the doses of IT morphine studied. There was
no difference in the number of episodes of reduced respi-
ratory rate (respiratory rate < 12) in the first 24 postoper-
ative hours in any group (Table 2). There was no
difference in the incidence of episodes of mild or moder-
ate hypoxemia between the three groups and all patients
whose SpO2 fell below 94% responded to 40% O2 via
facemask (Figure 3; Table 2). One patient, in the 300 μg
group, developed transient severe hypoxemia which
responded to an increase in inspired oxygen concentra-
tion.
There were no significant between group differences in the
incidence or severity of PONV (Figure 3; Tables 2, 3). Spe-
cifically, there was no between group difference in:
median PONV score at any time point (Table 3); time to
first request for anti-emetic therapy (Table 2); number of
patients that required anti-emetic therapy (Table 2); or
overall incidence of PONV (Figure 3).
There were no significant between group differences in the
incidence or severity of pruritus (Figure 3; Tables 2, 3).
Specifically, there was no between group difference in:
median pruritus score at any time point (Table 3);
number of patients that required anti-pruritic therapy
(Table 2); or overall incidence of pruritus (Figure 3).
There were no between group differences in sedation
scores (Table 3), or in the number of patients that devel-
oped significant sedation, which was defined as a sedation
score of 5 (Table 2). There were no between group differ-
ences in the requirement for urethral catheterization (Fig-
ure 3).
Discussion
This study demonstrates several important points. First,
doses of 200 μg and 300 μg IT morphine provide compa-
rable and effective postoperative analgesia in patients
undergoing elective total knee arthroplasty. Second, 100
μg of IT morphine was not as effective in providing anal-
gesia compared to the higher doses, and constitutes an
inadequate dose of IT morphine in this patient group.
Third, the incidence of respiratory depression and signifi-
cant postoperative hypoxemia is low. No patient that
received 200 μg of IT morphine developed severe arterial
hypoxaemia in this study, attesting to the safety of this
dose of IT morphine in this patient group. In summary,
Table 2: Data regarding requirement for postoperative analgesic, anti-emetic and anti-pruritic therapy and postoperative respiratory 
function.
Variable 100 μg IT Morphine 200 μg IT Morphine 300 μg IT Morphine P Value
Median time (mins) to first request for Rescue Analgesia 
(interquartile range)
442 (240, 1100) 607 (343, 1440) 857 (397, 1440) 0.2
Number of patients that requested Rescue Analgesia 17/20 12/20 12/20 0.1
Number of patients that requested anti-emetic therapy 7/20 9/20 11/20 0.4
Time to first request for Antiemetic Therapy (mins) 1117 ± 116 1037 ± 109 809 ± 138 0.2
Number of patients that required anti-pruritic therapy 0/20 3/20 3/20 0.2
Incidence of Respiratory Depression 
(Total episodes of Resp Rate < 12)
3/20 5/20 5/20 0.7
Number of episodes of mild arterial hypoxemia (SpO2 90 – 
94%)
8/20 9/20 8/20 0.9
Number of episodes of moderate arterial hypoxemia (SpO2 
85 – 90%)
1/20 0/20 1/20 0.6
Number of episodes of severe arterial hypoxemia (SpO2 < 
85%)
0/20 0/20 1/20 0.4
Median Sedation Score (interquartile range) 1 (1, 4) 1 (1, 4) 1 (1, 4) 0.9
Number of episodes of significant sedation 
(Total episodes of Sedation score = 5)
4/20 3/20 4/20 0.9
Notes: Data are presented as number of patients [from a maximum of 20] for each category unless otherwise stated. Data for time to request 
antiemetic therapy is presented as time in minutes +/- SEM. Sedation scores are presented as medians and interquartile ranges.
Abbreviations: IT, intrathecal; resp, respiratory; SpO2, arterial haemoglobin oxygen saturation; mins, minutesBMC Anesthesiology 2008, 8:5 http://www.biomedcentral.com/1471-2253/8/5
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200 μg IT morphine appears to provide comparable anal-
gesia to 300 μg, and appears to be the best balance
between analgesic efficacy and side-effect profile in this
patient group.
Our study clearly demonstrates that both 200 μg and 300
μg of IT morphine provide comparable analgesic efficacy
in patients undergoing elective knee arthroplasty. Both
regimens provided excellent analgesia and with a low
requirement for rescue analgesia in the first 24 hours post-
operatively. There was no difference in postoperative VAS
scores at any time point between patients receiving 200 μg
and 300 μg of IT morphine. In addition, there was no dif-
ference in the duration of analgesia provided by these
doses, or in the need for or amount of supplemental anal-
gesic therapy required. We have demonstrated that 100 μg
does not provide a comparable level of analgesia to that
provided by 200 μg or 300 μg of IT morphine, suggesting
that this constitutes an inadequate dose, and therefore
should not be used in this patient group.
The finding that 300 μg is an effective dose of IT morphine
in patients undergoing elective total knee arthroplasty has
been demonstrated in previous studies [2]. We demon-
strate for the first time that comparable levels of postoper-
ative analgesia can be achieved with 200 μg of IT
morphine. This finding contrasts to some extent with pre-
vious findings. Rathmell et al could not find evidence that
doses of IT morphine up to 300 μg provided significant
analgesia in this population [13]. However, this study
included patients undergoing both hip and knee arthro-
plasty, and studied multiple doses of IT morphine. Conse-
quently the numbers of patients in each group was
relatively small, reducing study power. Bowrey et al did
demonstrate that 500 μg intrathecal morphine produced
better analgesia than 200 μg after knee replacement [1].
Mean (+/- SEM) postoperative visual analogue scale (VAS) pain score in each group, measured every 4 hours, for the first 24  postoperative hours Figure 1
Mean (+/- SEM) postoperative visual analogue scale (VAS) pain score in each group, measured every 4 hours, 
for the first 24 postoperative hours. * Indicates significantly higher Area under VAS-Time curve compared to the 200 μg 
and 300 μg IT Morphine groups (P = 0.006, one way ANOVA).BMC Anesthesiology 2008, 8:5 http://www.biomedcentral.com/1471-2253/8/5
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However, the risk of serious side effects, particularly respi-
ratory depression is dose dependent [11,14]. Conse-
quently, ASA guidelines advocate that the lowest
efficacious dose of neuraxial opioids be used to minimize
this risk [14].
Respiratory depression, the most serious side-effect of IT
morphine, is more likely in the older patient, such as this
patient group [15]. Volunteer studies have demonstrated
that, while higher doses of IT morphine result in pro-
found and prolonged late respiratory depression, doses as
low as 200 μg may also produce significant respiratory
depression [11]. In additional similar studies, 300 μg of IT
morphine potently depressed the ventilatory response to
hypoxia [16]. These data emphasize the need to deter-
mine the lowest effective dose of IT morphine in this
patient population. In our study, one patient that received
300 μg IT morphine developed transient severe hypox-
emia, which responded to administration of 60% Oxygen.
None of the patients that received 100 μg or 200 μg IT
morphine developed severe hypoxemia in this study. This
confirms previous finding attesting to the safety of IT mor-
phine in this dose range [2,17-19].
The incidence and severity of PONV is a major concern
regarding the use of IT morphine [3,6]. In this study, there
was no between group difference in the incidence or sever-
ity of PONV, or in the need for anti-emetic therapy, fol-
lowing the use of 100 – 300 μg of IT morphine. This
suggests that PONV may be less problematic within this
dose range, and is in agreement with our previous finding
that 50 – 200 μg of IT morphine does not contribute to the
incidence of PONV in the setting of elective hip arthro-
plasty under spinal anaesthesia [17].
Dot plot of postoperative requirement for supplemental morphine over the first 24 postoperative hours for each patient in  each group Figure 2
Dot plot of postoperative requirement for supplemental morphine over the first 24 postoperative hours for 
each patient in each group. The middle line for each group represents the median value. * Indicates significantly 
higher morphine requirements compared to the 200 μg and 300 μg IT Morphine groups (P = 0.001, Kruskall-Wallis one way 
ANOVA on ranks).BMC Anesthesiology 2008, 8:5 http://www.biomedcentral.com/1471-2253/8/5
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Pruritus has been identified as a major side effect associ-
ated of IT opioids, and may contribute significantly to
patient discomfort [3,6]. It has been proposed that this
side effect is centrally mediated by μ-opioid receptors
[20]. In this study, the incidence of pruritus was high in all
groups, averaging 60% across the groups. There were no
between group differences in the incidence or severity of
pruritus, or in the need for anti-pruritic therapy, following
the use of 100 – 300 μg of IT morphine. This contrasts
with previous findings, from our group and others [7,17],
that the incidence of pruritus following intrathecal mor-
phine is dose dependent in patients following hip arthro-
plasty. Sedation did not appear to be a problem at the
doses of IT morphine used in this study. The incidence of
urinary retention did not appear to be related to the dose
of IT morphine administered.
An important limitation in regard to our data for the side-
effect profiles of the different doses of intrathecal mor-
phine is that the study was powered to detect differences
in analgesic efficacy, rather than in the incidence of side
effects. Therefore, it remains possible that between group
differences in more subtle, but nevertheless clinically
important side effects, were not detected in this study.
Caution is therefore warranted, particularly given the fact
that doses of IT morphine as low as 200 μg has been dem-
onstrated to produce significant respiratory depression in
other studies [11]. These findings emphasize the need for
appropriate monitoring of all patients receiving intrathe-
cal morphine as part of their postoperative analgesic regi-
men.
Conclusion
We conclude that administration of 200 μg provides
equally effective post operative analgesia as 300 μg of IT
morphine. Conversely, 100 μg of IT morphine provided
less effective postoperative analgesia in these patients. We
therefore recommend that 200 μg IT morphine be used
Incidence of side-effects, including arterial desaturation below 90%, urinary retention, postoperative nausea and vomiting  (PONV) and pruritus in each group over the first 24 postoperative hours (P > 0.05, Chi Square, for all comparisons) Figure 3
Incidence of side-effects, including arterial desaturation below 90%, urinary retention, postoperative nausea 
and vomiting (PONV) and pruritus in each group over the first 24 postoperative hours (P > 0.05, Chi Square, 
for all comparisons).BMC Anesthesiology 2008, 8:5 http://www.biomedcentral.com/1471-2253/8/5
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for postoperative analgesia in patients undergoing knee
arthroplasty.
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